Mode
Text Size
Log in / Sign up

Chagas disease associated with higher in-hospital mortality in adults hospitalized with heart failureHeart Failure Patients With Chagas Face Higher Death Risk In Hospital

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note higher in-hospital mortality associated with Chagas disease in heart failure patients.

This cohort study examined 910,128 heart failure hospitalizations within the Brazilian Unified Health System. The population consisted of adults hospitalized with heart failure. The exposure was Chagas disease, compared to non-Chagas heart failure. The primary outcome was in-hospital mortality. Follow-up was limited to the in-hospital period.

The main results showed higher in-hospital mortality in the Chagas group at 25% versus 12% for the non-Chagas group. The absolute numbers indicated 1,082 Chagas cases among 910,128 HF hospitalizations. The effect size was a hazard ratio of 1.54. The 95% confidence interval was 1.35 to 1.75. The p-value was less than 0.001. The direction of the effect was higher mortality in the Chagas group.

Safety and tolerability data were not reported. Adverse events, serious adverse events, discontinuations, and tolerability were not reported. Funding or conflicts of interest were not reported. The study design was observational, so causality cannot be established. The certainty of the evidence is limited by the observational nature of the data. Practice relevance was not reported. The study was conducted in the Brazilian Unified Health System.

Heart Failure Patients With Chagas Face Higher Death Risk In Hospital

Imagine walking into a hospital with a failing heart. You expect the best care possible. But for some patients, the outcome is far worse than for others. A new analysis of millions of hospital records reveals a stark reality. Patients with Chagas disease face a much higher risk of dying while they are still in the hospital.

This condition affects millions of people in Latin America. It is increasingly seen in other parts of the world too. Heart failure is a common reason for hospital visits. Yet, not all heart failure cases are created equal. Some types are harder to treat and carry a heavier burden.

Doctors have long known that Chagas disease damages the heart muscle. But the full picture of in-hospital risk was unclear. Many patients leave the hospital feeling better only to face complications later. Understanding the immediate danger inside the hospital is crucial for saving lives.

But here is the twist. The patients with Chagas disease were actually younger on average. They did not have the typical elderly profile seen in many heart studies. Despite being younger, they faced a much graver prognosis. Their hearts were often more damaged before they even arrived at the hospital door.

The biology behind this risk involves a parasite called Trypanosoma cruzi. This tiny invader attacks the heart muscle cells. Think of it like a factory where the workers are being sabotaged from the inside. The heart cannot pump blood efficiently. This leads to fluid buildup and severe strain on the organ.

The researchers looked at data from the Brazilian public health system. They reviewed records for nearly one million heart failure hospitalizations. The study covered four years of data from 2017 to 2021. They specifically searched for codes that identified Chagas disease alongside heart failure.

The numbers tell a sobering story. Out of 910,128 patients, only 1,082 had Chagas disease. That is a small fraction of the total. Yet, the mortality rate was shockingly different. About 25 percent of Chagas patients died in the hospital. In contrast, only 12 percent of other heart failure patients died during their stay.

After adjusting for age and other factors, the risk remained high. Having Chagas disease increased the odds of death by more than half. This means the disease itself drives the risk, not just other health issues. The heart simply cannot handle the stress of a hospital stay as well as a healthy heart would.

This doesn't mean this treatment is available yet.

Experts say this finding changes how we view the disease. It is not just a chronic condition to manage at home. It is a high-risk state that demands immediate attention. Current treatments exist but may not be enough for everyone. The gap between available drugs and the severity of the disease is wide.

What does this mean for you? If you live in an endemic area, ask your doctor about testing. Early detection can change the course of the disease. Knowing the risk helps doctors plan better care strategies. It also prepares families for what might happen during a hospital visit.

The study has some limits. It used data from one country. Results might differ in other regions with different health systems. Also, the study looked at hospital deaths only. It did not track long-term survival after discharge. More research is needed to understand the full picture.

The road ahead involves better drugs and targeted therapies. Scientists are working on new ways to kill the parasite without harming the heart. Until then, awareness is the best tool we have. Knowing the risk saves lives. Every patient deserves the chance to survive their hospital stay.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Chagas cardiomyopathy remains a major cause of heart failure (HF) in endemic regions and is increasingly recognized globally, yet data on in-hospital outcomes are limited. Objective: To assess whether Chagas disease is associated with higher in-hospital mortality among patients hospitalized with HF. Methods: We analyzed a nationwide administrative database from the Brazilian Unified Health System (DATASUS/SIHSUS), including adults hospitalized with HF between April 2017 and August 2021. HF was identified using ICD10 code I50.x and Chagas disease using B57.x. The primary outcome was in hospital mortality, evaluated using multivariable Cox models. Results: Among 910,128 HF hospitalizations, 1,082 (0.12%) were associated with Chagas disease. Patients with Chagas were younger but had a more complex clinical profile and higher resource use. In-hospital mortality was higher in the Chagas group (25% vs 12%; p<0.001). After adjustment, Chagas disease remained independently associated with mortality (HR 1.54; 95% CI 1.35, 1.75; p<0.001). Conclusions: In this large real world cohort, Chagas disease was associated with higher in-hospital mortality and greater healthcare utilization. These findings reinforce the high risk nature of Chagas cardiomyopathy and point to the need for more targeted treatment strategies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.